Boehringer Ingelheim– tag –
-
Boehringer Ingelheim Initiates Phase II for BI 3034701, a Novel GLP-1/GIP/NPY2 Triple Agonist, Reshaping Obesity Treatment
Life Science Daily News USA Overview Boehringer Ingelheim initiated a Phase II trial in July 2026 for BI 3034701 (NCT07662122), a groundbreaking triple agonist targeting GLP-1, GIP, and the NPY2 receptor, signaling a new direction beyond... -
Boehringer Ingelheim Initiates Phase II Trial for BI 3034701, a Potential First-in-Class Triple Receptor Agonist for Obesity
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has launched a Phase II clinical trial for BI 3034701, an investigational triple GLP-1/GIP/NPY2 receptor agonist targeting patients with obesity and overweight. This molecule rep... -
Boehringer Ingelheim’s First-in-Class Obesity Drug BI 3034701 Enters Phase II, Triggers €10M Milestone Payment to Gubra
Boehringer Ingelheim Germany Overview Boehringer Ingelheim has initiated a Phase II clinical trial for BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist for patients with obesity and overweight. This investiga... -
Boehringer Ingelheim Announces Promising Interim Phase 2 Results for Obesity Treatment BI 3034701: A Potential First-in-Class Triple Receptor Agonist
Boehringer Ingelheim Germany Overview Boehringer Ingelheim announced promising interim results from its Phase 2 clinical trial for BI 3034701, a novel triple receptor agonist for obesity. BI 3034701, targeting GLP-1, GCG, and GIP recepto... -
Boehringer Ingelheim Fuels Immunai’s AI with $15M to Unlock T-Cell Secrets for Cancer, Autoimmune Drug Discovery
Fierce Biotech USA Overview Boehringer Ingelheim (BI) has invested $15 million in Immunai's advanced AI platform, initiating a collaborative research agreement. This partnership aims to accelerate drug discovery for cancer and autoimmune... -
Zealand Pharma Advances Obesity Pipeline with Phase 3 Progress, Leveraging Roche and Boehringer Ingelheim Partnerships
WhaleWisdom Global Overview Zealand Pharma, in partnership with Roche, is progressing its obesity drug candidate petrelintide into Phase 3 trials following favorable Phase 2 data on weight loss and tolerability. Separately, Boehringer In...
1